Allergan's sales woes are a tipoff to declining sales of cosmetic pharmaceuticals in general: Despite predictions that Botox would be recession-proof, the wrinkle fighter lost 3 percent of its sales in the fourth quarter to come in at $329 million, and the company's dermal fillers saw revenues sink by 8.8 percent to $56 million. Experts predict the trend will apply at other companies, too. Report